Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.23M$9.23Mderived−25.7% vs Q4 2024 Net Income$22.66M$22.66Mderived+1,104.5% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$6,045,000−23.5% Operating Incomederived$1,578,000−23.4% Operating Cash Flowderived$2,138,000+80.6% Free Cash Flowderived$2,100,000+99.1% Margins · derivedGross margin65.5%+1.8 pt vs Q4 2024
Operating margin17.1%+0.5 pt vs Q4 2024
Net margin245.6%+230.4 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 30, 2026 · 89 d after period end